SCHEMBL8007652

SCHEMBL8007652

CN1CCN(C(=O)Cc2ccc3ccccc3c2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.61
TSHR P16473 2/20 0.58
HPGD P15428 1/20 0.58
GPR183 P32249 1/20 0.56
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
CHKA P35790 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.51
LMNA P02545 1/20 0.50
BCHE P06276 1/20 0.50
HTR2C P28335 1/20 0.50
ADRA1A P35348 1/20 0.50
HTR2B P41595 1/20 0.50
HTR6 P50406 1/20 0.50
SLC6A3 Q01959 1/20 0.50
HDAC3 O15379 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7620223 0.99 MAPT (0.59) MAPTTSHRHPGDGPR183MEN1
SCHEMBL16578041 0.86 HSD11B1 (0.69) GPR183MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL9410731 0.85 GPR183 (0.56) MAPTHPGDGPR183MEN1KMT2A
SCHEMBL18195121 0.85 GPR183 (0.53) GPR183MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL14198735 0.84 SLC6A4 (0.56) HPGDGPR183MEN1KMT2ASMN1; SMN2
SCHEMBL8984763 0.83 GPR183 (0.54) HPGDGPR183MEN1KMT2ASMN1; SMN2
SCHEMBL6707299 0.81 HSD11B1 (0.71) MAPTTSHRHPGDGPR183MEN1
SCHEMBL16002918 0.80 HDAC3 (0.55) GPR183MEN1KMT2AHDAC3HDAC1
SCHEMBL20612386 0.79 HPGD (0.55) TSHRHPGDMEN1KMT2ACHKA
SCHEMBL12431998 0.79 HDAC1 (0.49) GPR183MEN1KMT2ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160318856-A1 Substituted Urea eIF2alpha Kinase Activators NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-11-03 US disclosed
WO-2015038778-A1 SUBSTITUTED UREA EIF2α KINASE ACTIVATORS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2015-03-19 WO disclosed
WO-2000028993-A1 SEROTONIN LIGANDS AS PRO-ERECTILE COMPOUNDS NORTRAN PHARMACEUTICALS, INC. (CA) 2000-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318856-A1 Substituted Urea eIF2alpha Kinase Activators EIF2AK1, EIF2A, EIF4A2 MAPT 1799/4885TSHR 3637/4885HPGD 3774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.